Monitoring of Heparin Therapy with the Activated Partial Thromboplastin Time and Chromogenic Substrate Assays

Summary

Heparin therapy was monitored with the activated partial thromboplastin time (APTT) and with chromogenic substrate assays (factor Xa and factor Ha inhibition) in 100 plasma samples from 47 patients. Heparin concentrations were classified as being below, within or above a defined therapeutic range (TR; 0.2-0.55 units heparin/ml). In a first group of patients (A), all three assays allocated the plasma heparin levels to the same concentration interval with respect to the TR. The most frequent diagnoses in group A were uncomplicated arterial or venous thromboembolism, myocardial infarction with limited tissue necrosis, cardiac surgery without major complications and successfully treated infectious disease. In a second group of patients (B), the results of APTT suggested higher heparin concentrations with respect to the TR than the chromogenic assays. Predominant diagnoses were severe infectious diseases, severe liver disorders, extensive myocardial infarction and postoperative complications after cardiac surgery. The discrepancy between heparin concentrations determined by either APTT or the chromogenic substrate assays is most likely due to a non-heparin related prolongation of APTT caused by the underlying disease.

Keywords

Heparin therapy - Heparin monitoring - Chromogenic substrate assays - Activated partial thromboplastin time - Acquired coagulation disorders

• References

• 1 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin therapy with the activated partial thromboplastin time. New Engl J Med 1972; 287: 324-327
• 2 Bounameaux H, Marbet GA, Lammle B, Eichlisberger R, Duckert F. Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time and plasma heparin concentration, and analysis of the behaviour of antithrombin III. Amer J Clin Pathol 1980; 74: 68-73
• 3 Brandt JT, Triplett DA. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Amer J Clin Pathol 1981; 76 (suppl): 530-537
• 4 Salzman EW, Deykin D, Mayer Shapiro R, Rosenberg R. Management of heparin therapy. Controlled prospective trial. New Engl J Med 1975; 292: 1046-1050
• 5 Suchman AL, Griner PF. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Int Med 1986; 104: 810-816
• 6 Teien AN, Abildgaard U. On the value of the activated partial thromboplastin time (APTT) in monitoring heparin therapy. Throm- bos Res 1976; 35: 592-596
• 7 Penner JA. Experience with a thrombin clotting time for measuring heparin activity. Amer J Clin Pathol 1974; 61: 645-653
• 8 Hoppensteadt DA, Walenga JM, Fareed J. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. Semin Thrombos Hemostas 1985; 11: 112-120
• 9 Juhan-Vague I, Riera H, Aillaud MF, Verdet D, Sambuc R. Measurement of blood heparin levels - variation in results with assay method. Thrombos Hemostas 1982; 47: 295
• 10 Larsen ML, Abildgaard U, Teien AN, Gjersdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip- Arg-pNA (S-2238). Thrombos Res 1978; 13: 285-288
• 11 Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thrombos Res 1976; 8: 413-416
• 12 Dacie JV, Lewis SM. Laboratory control of anticoagulant and thrombolytic therapy. In: Practical Haematology. 6th ed. pp. 265-266 Churchill Livingstone, Edinburgh; London, Melbourne and New York: 1984
• 13 Lang M, Fey MF, Furlan M, Beck EA. Uberwachung der Heparin- therapie mit der Thrombinzeit und der aktivierten partiellen Throm- boplastinzeit - ein Vergleich. Schweiz med Wschr 1986; 116: 1681-1684
• 14 Aasen AO, Smith-Erichsen N, Amundsen E. Plasma kallikrein-kinin system in septicemia. Arch Surg 1983; 118: 343-346
• 15 Colman RW, Wong PY. Participation of Hageman factor dependent pathways in human disease states. Thrombos Res 1977; 38: 751-775
• 16 Ragni MV, Lewis JH, Hasiba U, Spero JA. Prekallikrein (Fletcher factor) deficiency in clinical disease states. Thrombos Res 1980; 18: 45-54
• 17 Mombelli G. Probleme der Heparindosierung. Schweiz med Wschr 1984; 114: 524-528
• 18 Poller L, Thomson JM, Yee KF. Heparin and partial thromboplastin time: an international survey. Brit J Haemat 1980; 44: 161-165
• 19 Shapiro GA, Huntzinger SW, Wilson III JE. Variation among commercial activated partial thromboplastin time reagents in response to heparin. Amer J Clin Pathol 1977; 67: 477-480
• 20 Glynn M FX. Heparin monitoring and thrombosis. Amer J Clin Pathol 1979; 71: 397-400
• 21 Green D, Hougie C, Kazmier FJ, Lechner K, Mannucci PM, Rizza CR, Sultan Y. Report of the working party on acquired inhibitors of coagulation: studies of the “lupus” anticoagulant. Thromb Haemostas 1983; 49: 144-146
• 22 Lammle B, Tran TH, Ritz R, Duckert F. Plasma prekallikrein, factor XII, antithrombin III, Crinhibitor and alpha-2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Amer J Clin Pathol 1984; 82: 396-404
• 23 Mason JW, Kleeberg U, Dolan P, Colman RW. Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann Int Med 1970; 73: 545-551
• 24 Saito H, Poon MC, Vicic W, Goldsmith jr GH. Menitove J E. Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. J Lab Clin Med 1978; 92: 84-95